Suppr超能文献

边缘区淋巴瘤的转化风险及相关生存结局:一项全国性研究。

Transformation risk and associated survival outcome of marginal zone lymphoma: A nationwide study.

机构信息

Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.

West China School of Medicine, Sichuan University, Chengdu, Sichuan, 610041, China.

出版信息

Ann Hematol. 2024 Oct;103(10):4211-4222. doi: 10.1007/s00277-024-05688-x. Epub 2024 Mar 9.

Abstract

Histological transformation into an aggressive B-cell lymphoma indicates a poor survival outcome for patients with indolent marginal zone lymphoma (MZL), which has been less studied. Large-scale data with long-term follow-up to investigate MZL transformation is limited. Here, by reporting a US-Nationwide cohort of 30,619 MZL patients diagnosed between 2000 and 2019, we found that transformation occurred in 2.08% (N = 624) of MZL cases, with the transformation incidence of 3.1 per 1,000 person-years. Advanced Ann Arbor stage, nodal MZL (NMZL) and splenic MZL (SMZL) were associated with an elevated risk of transformation. Certain subtype-specific characteristics, such as non-gastric extra-nodal MZL (vs. gastric, HR, 1.51, 95%CI 1.13-2.04; p = 0.006), and receiving splenectomy for SMZL (HR, 2.04, 95%CI 1.28-3.26; p = 0.003), also indicated a higher risk of transformation. Besides, transformation independently increased the overall mortality risk (HR, 1.38, 95%CI 1.24-1.53, p < 0.001), especially the higher lymphoma-caused mortality risk (HR, 3.21, 95%CI 2.81-3.67, p < 0.001). Transformation was also associated with a higher percentage of lymphoma-caused deaths. The post-transformation prognostic analyses demonstrated that female gender and age ≥ 65 years independently affected patients' mortalities. These findings, based on the largest cohort to date, contribute to a better understanding of transformed MZL, and provide valuable reference points for guidelines and patient counseling.

摘要

惰性边缘区淋巴瘤(MZL)发生侵袭性 B 细胞淋巴瘤转化预示着患者生存结局较差,然而目前对其研究较少。缺乏针对 MZL 转化的大规模、长期随访的大型数据。在此,我们通过报告一项美国全国范围内的 30619 例 2000 年至 2019 年间诊断为 MZL 的患者队列,发现有 2.08%(N=624)的 MZL 病例发生转化,每 1000 人年有 3.1 例转化。晚期 Ann Arbor 分期、结外边缘区淋巴瘤(NMZL)和脾边缘区淋巴瘤(SMZL)与转化风险增加相关。某些亚型特异性特征,如非胃结外边缘区淋巴瘤(与胃边缘区淋巴瘤相比,HR,1.51,95%CI 1.13-2.04;p=0.006)和因 SMZL 而行脾切除术(HR,2.04,95%CI 1.28-3.26;p=0.003),也提示转化风险更高。此外,转化独立增加了总死亡率风险(HR,1.38,95%CI 1.24-1.53,p<0.001),特别是淋巴瘤导致的死亡率风险(HR,3.21,95%CI 2.81-3.67,p<0.001)。转化也与更高比例的淋巴瘤导致的死亡相关。转化后的预后分析表明,女性和年龄≥65 岁独立影响患者的死亡率。这些基于迄今为止最大队列的研究结果,有助于更好地了解转化性 MZL,并为指南和患者咨询提供有价值的参考点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验